uniQure (QURE) has provided investors with "a compelling glimpse at what the future hold for Hemophilia B patients" after issuing an update on its AMT-061 dose confirmation study, according to H.C. Wainwright analyst Debjit Chattopadhyay. The mean Factor IX activity at six weeks was 31%, which is on par with Spark Therapeutics' (ONCE) SPK-9001, said Chattopadhyay. The analyst, who thinks AMT-061 is "living up to high expectations" and views it being positioned as "not only the best-in-class one-and-done solution, but also, the first to market," keeps a Buy rating and $48 price target on uniQure shares.